Get the Stockscreener App
0.00
100.00%
-5.54
After Hours:
5.54
5.54
+
Alimera Sciences Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East operations are managed as three operating segments: U.S., International and Operating Cost It generates maximum revenue from U.S. Segment.
See More
Previous Close:
$5.54
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$301.29M
Revenue:
$80.75M
Net Income/Loss:
$-20.13M
P/E Ratio:
0.00
EPS:
-2.1622
Net Cash Flow:
$-89.79M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$5.65
Alimera Sciences Inc Stock (ALIM) Company Profile
Name
Alimera Sciences Inc
Sector
Phone
678-990-5740
Address
6310 TOWN SQUARE, ALPHARETTA, GA
Compare ALIM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALIM
Alimera Sciences Inc
|
0.00 | 301.29M | 80.75M | -20.13M | -89.79M | -2.1622 |
|
ZTS
Zoetis Inc
|
172.24 | 77.71B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.52 | 43.05B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.32 | 42.23B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.06 | 19.33B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
152.42 | 15.43B | 2.24B | 385.90M | 440.10M | 3.73 |
Alimera Sciences Inc Stock (ALIM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-19 | Initiated | Craig Hallum | Buy |
| Apr-27-17 | Initiated | Rodman & Renshaw | Buy |
| Nov-17-14 | Initiated | Summer Street Research | Buy |
| Sep-29-14 | Reiterated | Northland Capital | Outperform |
| Oct-28-13 | Upgrade | Cowen | Market Perform → Outperform |
| Oct-08-13 | Initiated | Northland Capital | Outperform |
| Nov-14-11 | Downgrade | Rodman & Renshaw | Mkt Outperform → Mkt Perform |
| Dec-27-10 | Reiterated | Oppenheimer | Outperform |
| Oct-11-10 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jun-02-10 | Initiated | Oppenheimer | Outperform |
View All
Alimera Sciences Inc Stock (ALIM) Latest News
Alimera Sciences Announces Data from 19 Iluvien(R) Studies to be Presented at 2018 ARVO - ACCESS Newswire
ALIMERA SCIENCES INC to Host Earnings Call - ACCESS Newswire
Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal - MSN
Actinic Keratosis Treatment Market 2034: EMA, PDMA, FDA Approvals, Prevalence, Clinical Trials, Medication, Therapies, and Companies by DelveInsight - The Globe and Mail
ANIPANI Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity - The Manila Times
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc.ALIM - GuruFocus.com
Autoimmune Uveitis Market Will Accelerate Rapidly with - openPR
Uveitis Market Forecasted for Major Expansion by 2031 | Novartis - openPR
Eye Inflammation Treatment Market Overall Study Report - openPR
Diabetic Macular Edema Market Key Players AnalysisNovartis - openPR
Ophthalmic Steroids Drugs Market 2024-2031 Porter's Five - openPR
ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance - GlobeNewswire
ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.06% - GlobeNewswire
ANI Pharmaceuticals introduces generic Estradiol Gel By Investing.com - Investing.com South Africa
ANI Pharmaceuticals introduces generic Estradiol Gel - Investing.com
ANI Pharmaceuticals to Present New Data Highlighting - GlobeNewswire
ANI Pharmaceuticals to Present New Data Highlighting Membranous Nephropathy Research at American Society of Nephrology Kidney Week 2024 - StockTitan
ANI Pharmaceuticals price target raised to $62 from $60 at Truist - Yahoo Finance
ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market - Seeking Alpha
StockNews.com Begins Coverage on Alimera Sciences (NASDAQ:ALIM) - Defense World
Stonepine Capital Management LLC Sells 539,256 Shares of Alimera Sciences, Inc. (NASDAQ:ALIM) - Defense World
20,394 Shares in Alimera Sciences, Inc. (NASDAQ:ALIM) Acquired by Rhumbline Advisers - Defense World
Alimera Sciences (NASDAQ:ALIM) Coverage Initiated at StockNews.com - Defense World
ANI Pharmaceuticals Announces the FDA Approval and Launch of Ketoconazole Shampoo, 2% - StockTitan
On the Move: Mergers, Management Moves, and More - Community News
Glazer Capital LLC Makes New $3.07 Million Investment in Alimera Sciences, Inc. (NASDAQ:ALIM) - Defense World
Allarity Therapeutics, Inc Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Allarity Therapeutics, - Longview News-Journal
ALXO stock touches 52-week low at $1.87 amid market challenges - Investing.com
ALLR CLASS ACTION REMINDERRobbins LLP Reminds - GlobeNewswire
Great Point Partners LLC Increases Stake in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Stocks Under $20: Arlo Technologies, Applied Optoelectronics - Schaeffers Research
Allison Transmission (NYSE:ALSN) Reaches New 1-Year High at $92.93 - MarketBeat
Market Watch: Alignment Healthcare Inc (ALHC)’s Noteworthy Drop, Closing at 10.98 - The Dwinnex
What is the investor’s view on Alx Oncology Holdings Inc (ALXO)? - US Post News
A stock that deserves closer examination: Allarity Therapeutics Inc (ALLR) - US Post News
Berkley W R Corp Purchases New Shares in Alchemy Investments Acquisition Corp 1 (NASDAQ:ALCY) - MarketBeat
Market Momentum: Allarity Therapeutics Inc (ALLR) Registers a 1.36 Increase, Closing at 2.24 - The Dwinnex
Intech Investment Management LLC Has $1.74 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Rhumbline Advisers Purchases 87 Shares of Alexander’s, Inc. (NYSE:ALX) - Defense World
Insider Sale Alert: Aldeyra Therapeutics Inc [ALDX] – Is it Time to sell? - Knox Daily
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit - The Bubble
Elevai Labs shares tumble on pricing of new stock offering - The Business Journals
Alector (NASDAQ:ALEC) Shares Down 5.6% - Defense World
Integral Health Asset Management LLC Buys 20,000 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
ALLR INVESTOR ALERT: Edelson Lechtzin LLP Urges Allarity - GlobeNewswire
Alignment Healthcare (NASDAQ:ALHC) Shares Gap Down to $11.43 - Defense World
Market Update: Alx Oncology Holdings Inc (ALXO) Sees Negative Movement, Closing at 2.07 - The Dwinnex
Wall Street analysts’ outlook for Arcellx Inc (ACLX) - SETE News
In the Green: Longboard Pharmaceuticals Inc (LBPH) Closes at 33.89, Up/Down 1.47 from Previous Day - The Dwinnex
Why Elevai Labs (ELAB) Stock Is Down 60% Today - Benzinga
Alimera Sciences Inc Stock (ALIM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.76%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):